Congenital Methemoglobinemia Type II—Clinical Improvement with Short‐Term Methylene Blue Treatment. Issue 3 (17th November 2015)

• Record Type: Journal Article
• Authors: Cooper, Monica S.; Randall, Melinda; Rowell, Margaret; Charlton, Margaret; Greenway, Anthea; Barnes, Chris
• Is Part Of: Pediatric blood & cancer. Volume 63:Issue 3(2016)
• Page Start: 558
• Page End: 560
• Publication Date: 2015-11-17
• Subjects: methemoglobinemia -- methemoglobin -- cytochrome‐b(5)reductase -- methylene blue -- cyanosis; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25791
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract : We report a case of prophylactic management with methylene blue (MB) in an almost 4‐year‐old male with congenital methemoglobinemia type II. He has a CYB5R3 compound heterozygote mutation, causing a cytochrome‐b(5) reductase deficiency. Since the MB treatment regimen has commenced, his methemoglobin level has been significantly lower. He has shown modest behavioral improvements (as assessed on the Achenbach behavior report scales). There have been no iatrogenic side effects. These findings are encouraging for symptomatic improvement with regular prophylactic MB treatment but represent a single case report, which must be interpreted with caution.